HSBC raised the firm’s price target on Novo Nordisk (NVO) to $54 from $47 and keeps a Hold rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, “even more so if AI panic kicks in.” HSBC’s preferred stocks are “growth bucket ideas,” but says “fallen angels and value could work as well.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk
- Mixed options sentiment in Novo Nordisk with shares down 0.27%
- Why is Biotech Stock iBio Up over 50%?
- Can Life Wave Sciences Disrupt the Obesity Market? WVE Soars 147% after Initial Results
- Novo Nordisk price target lowered to DKK 350 from DKK 500 at JPMorgan